Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.82
-$2.71(-4.69%)
At close: 4:00 PM EST
$15.82
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)924.39K
Market Cap
$867.20M
Enterprise Value$832.67M
Total Cash (Recent Filing)$956.39M
Total Debt (Recent Filing)$21.57M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 11, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,984,352
10 Day Avg. Volume881,194
30 Day Avg. Volume924,386
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue38.53
Enterprise Value/Gross Profit71.15
Enterprise Value/Ebitda-7.40
Forecast
1Y Price Target
$31.00Price Target Upside95.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.72
Revenue Forecast (FY)$32.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetJanux’s very low debt-to-equity (~0.02) and substantial equity provide durable financial flexibility for a clinical-stage biotech. This conserves optionality to fund R&D, absorb development setbacks, and pursue partnerships or milestone financing without immediate solvency pressure.
Improving Revenue MomentumA 20.9% TTM revenue rebound indicates improving top-line momentum for a company without commercial products, likely from collaborations, milestones or service revenue. Sustained revenue improvement can extend runway, validate program progress, and increase partner or investor confidence over the medium term.
Stable Corporate GovernanceHigh shareholder participation, board continuity, and ratification of auditors and compensation signal stable governance. For a clinical-stage company, consistent oversight reduces execution risk, supports orderly succession planning, and aids credibility with investors and potential partners in future financings or collaborations.
Bears Say
Negative Cash Flow / Rising BurnPersistent negative operating and free cash flow, with worsening FCF in the TTM, reflect an ongoing cash burn that heightens financing dependency. Over 2–6 months this increases dilution and execution risk if capital markets or partnership milestones do not provide timely funding to sustain clinical programs.
Deep Operating LossesMaterial operating losses and very negative net margins show R&D and operating costs far exceed revenues. This structural unprofitability consumes shareholder capital and limits internal funding capacity, making program progress contingent on external financing or partnerships over the medium term.
Senior Clinical Leadership ChangeThe departure of the CMO introduces longer-term execution risk in clinical development and regulatory interactions. Even with interim coverage, replacing senior clinical expertise can delay study decisions, site interactions, or regulatory strategy, affecting trial timelines and program de-risking over several months.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $867.20M.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 39 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.161.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,984,352 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (95.95% Upside)
$31.00 (95.95% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 289.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.86%
12-Months-Change
Fundamentals
Return on Equity
-11.85%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$31.00
▲(95.95% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
19.51% Insiders
13.19% Mutual Funds
44.93% Other Institutional Investors
10.08% Public Companies and
Individual Investors